Trials / Recruiting
RecruitingNCT07427563
Cerebellar Deep Brain Stimulation for the Treatment of Ataxia
Cerebellar Deep Brain Stimulation for the Treatment of Refractory Ataxia and Gait Disorders: Pilot Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Abnormal gait is often associated with immobility and falls, which in turn lead to loss of functional independence and death. While gait disorders may arise from many different etiologies, dysfunction of the cerebellum (a part of the brain with the function of coordination of movement) leading to gait disorders results in distinct features. Gait ataxia is a specific type of neurological gait disorder and is defined as the presence of abnormal, uncoordinated movements associated with gait. To date, there are limited treatments for ataxia and/or gait disorders. Deep brain stimulation (DBS) is a neurosurgical tool that has been widely used for over twenty years, mainly to treat Parkinson's disease, dystonia, and essential tremor. In this study, we aim to implant DBS in patients with ataxia and/or gait disorder in the cerebellum area, and electrically stimulate them in a titratable and ultimately reversible manner. This study is divided into 3 phases: pre-operative, operative and post-operative phase. The purpose of this pilot study is to evaluate the safety, feasibility, and to validate the DBS of cerebellar cortical and deep nuclei in patients with treatment refractory ataxia. Twelve(12 ) patients will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Deep Brain Stimulation | Standard of care Neurosugical implantation of Deep Brain Stimulation under general anesthesia |
Timeline
- Start date
- 2023-03-02
- Primary completion
- 2030-12-31
- Completion
- 2035-12-31
- First posted
- 2026-02-23
- Last updated
- 2026-02-23
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07427563. Inclusion in this directory is not an endorsement.